Publicaciones en las que colabora con Belén Vidriales Vicente (11)

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

2018

  1. Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

    Leukemia, Vol. 32, Núm. 4, pp. 971-978

2017

  1. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials

    Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910

  2. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Blood, Vol. 127, Núm. 25, pp. 3165-3174

  3. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

    Blood, Vol. 127, Núm. 15, pp. 1896-1906

2015

  1. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2012

  1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

2011

  1. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Leukemia, Vol. 25, Núm. 4, pp. 697-706